

Onyee Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8556366/publications.pdf>

Version: 2024-02-01

63
papers

725
citations

840776

11
h-index

580821

25
g-index

64
all docs

64
docs citations

64
times ranked

1317
citing authors

#	ARTICLE	IF	CITATIONS
1	Cold but not sympathomimetics activates human brown adipose tissue in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10001-10005.	7.1	264
2	A Review of Autologous Stem Cell Transplantation in Lymphoma. Current Hematologic Malignancy Reports, 2017, 12, 217-226.	2.3	73
3	Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Advances, 2020, 4, 530-538.	5.2	60
4	Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Advances, 2021, 5, 1017-1028.	5.2	41
5	Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Advances, 2020, 4, 3435-3442.	5.2	30
6	Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. Future Oncology, 2019, 15, 257-269.	2.4	25
7	Genomic characteristics and prognostic significance of co-mutated <i>ASXL1</i> and <i>SRSF2</i> acute myeloid leukemia. American Journal of Hematology, 2021, 96, 462-470.	4.1	19
8	Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leukemia Research, 2019, 84, 106194.	0.8	18
9	Chronic myelomonocytic leukemia diagnosis and management. Leukemia, 2021, 35, 1552-1562.	7.2	18
10	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research, 2020, 93, 106367.	0.8	15
11	Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. Clinical Cancer Research, 2021, 27, 6095-6105.	7.0	14
12	Burkitt Lymphoma Presenting as an Intracardiac Mass: Case Report and Review of Literature. American Journal of Case Reports, 2016, 17, 553-558.	0.8	13
13	PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia, 2021, 35, 286-288.	7.2	11
14	Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 2739-2751.	7.2	10
15	Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report. Journal of Medical Case Reports, 2017, 11, 100.	0.8	9
16	Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 149-149.	1.4	9
17	Coccidioidomycosis with Pericardial Involvement: Case Report and Literature Review. American Journal of Medicine, 2016, 129, e21-e25.	1.5	8
18	Validation of the international working group proposal for <i>SF3B1</i> mutant myelodysplastic syndromes. Blood, 2021, 138, 989-992.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax. <i>Blood</i> , 2019, 134, 1357-1357.	1.4	7
20	MYC Overexpression is Associated with an Early Disease Progression from MDS to AML. <i>Leukemia Research</i> , 2021, 111, 106733.	0.8	6
21	Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2741-2741.	1.4	5
22	Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. <i>Leukemia</i> , 2022, 36, 1189-1192.	7.2	5
23	Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e467-e476.	0.4	5
24	Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3895-3895.	1.4	4
25	Hodgkin Lymphoma Mimicking Osteomyelitis. <i>Case Reports in Oncology</i> , 2017, 10, 542-547.	0.7	3
26	Luspatercept in the treatment of lower-risk myelodysplastic syndromes. <i>Future Oncology</i> , 2021, 17, 1473-1481.	2.4	3
27	CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3894-3894.	1.4	3
28	Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1368-1368.	1.4	3
29	Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 217-217.	1.4	3
30	Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1-Mutated ELN Favorable Risk AML. <i>Blood</i> , 2021, 138, 686-686.	1.4	3
31	<i>IDH</i> Mutations Are Enriched in Myelodysplastic Syndromes Patients with Severe Neutropenia: A Potential Targeted Therapy. <i>Blood</i> , 2021, 138, 1526-1526.	1.4	3
32	Assessing the Role of Venetoclax in Combination with Hypomethylating Agents in Higher Risk Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 536-536.	1.4	3
33	Incidence of Pleural Effusion with Dasatinib and the Effect of Switching Therapy to Bosutinib in Patients with Chronic Phase CML. <i>Blood</i> , 2021, 138, 1484-1484.	1.4	3
34	Mixed phenotype acute leukemia with t(9;22): success with nonacute myeloid leukemia-type intensive induction therapy and stem cell transplantation. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 435-439.	0.5	2
35	Can increased immunogenicity in chronic myeloid leukemia improve outcomes?. <i>Expert Review of Hematology</i> , 2019, 12, 225-233.	2.2	2
36	Moving towards a uniform risk stratification system in CMML - How far are we?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101131.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts. Blood, 2019, 134, 4244-4244.	1.4	2
38	Clinical Characteristics and Outcome of Patients with EZH2- Mutant Myelodysplastic Syndromes. Blood, 2021, 138, 1531-1531.	1.4	2
39	Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. American Journal of Hematology, 2022, 97, .	4.1	2
40	Case of relentless chronic phase of chronic myeloid leukaemia. BMJ Case Reports, 2016, 2016, bcr2016215370.	0.5	1
41	Survival Impact of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive (Ph+) de novo Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S296-S297.	0.4	1
42	Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e52-e56.	0.4	1
43	Biology and Pathophysiology of MDS with del(5q). , 2020, , 43-54.		1
44	Outcomes and Side Effect Profile of Ponatinib in Treatment of Chronic Myeloid Leukemia (CML): A Retrospective Single-Center Experience. Blood, 2018, 132, 4259-4259.	1.4	1
45	ASXL1/SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes. Blood, 2019, 134, 2598-2598.	1.4	1
46	Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia. Blood, 2019, 134, 3382-3382.	1.4	1
47	Outcomes of Patients Treated with CPX-351 As First Line Therapy for AML Based on Their Antecedent History of Myeloid Malignancy. Blood, 2021, 138, 1251-1251.	1.4	1
48	Treatment Free Remission in Patients with Chronic Phase CML: A Single Center Experience. Blood, 2021, 138, 3612-3612.	1.4	1
49	Different Treatment Approaches to Blast Phase-Myeloproliferative Neoplasms. Blood, 2021, 138, 3641-3641.	1.4	1
50	Impact of the Number of Consolidation Chemotherapy Cycles Prior to Allogeneic Stem Cell Transplant for Adults with Acute Myeloid Leukemia in First Remission. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S222.	0.4	0
51	Ring Sideroblast Quantification is Highly Predictive of TP53 Mutation in MDS with Excessive Blasts with Prognostic Implications. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S344-S345.	0.4	0
52	Clinical Significance of MYC Oncoprotein Expression on Survival Outcome in Secondary Acute Myeloid Leukemia (sAML). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S205-S206.	0.4	0
53	Outcome of Immune-Suppressive Therapy (IST) and Hematopoietic Stem Cell Transplantation (SCT) in Patients with Aplastic Anemia: A Retrospective Single Center Experience. Blood, 2016, 128, 5081-5081.	1.4	0
54	Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome. Blood, 2019, 134, 4621-4621.	1.4	0

#	ARTICLE	IF	CITATIONS
55	RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 2052-2052.	1.4	0
56	High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients. Blood, 2021, 138, 2377-2377.	1.4	0
57	A Focus on Phenotype and Genotype: Racial /Ethnic Disparities in Myelodysplastic Syndromes. Blood, 2021, 138, 1985-1985.	1.4	0
58	Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 4138-4138.	1.4	0
59	Outcomes of Patients with AML Treated with CPX-351 Based on the 2017 ELN Risk Stratification. Blood, 2021, 138, 1250-1250.	1.4	0
60	Outcomes By Best Response with Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia. Blood, 2021, 138, 2292-2292.	1.4	0
61	Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia. Blood, 2021, 138, 3658-3658.	1.4	0
62	Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes. Blood, 2021, 138, 1984-1984.	1.4	0
63	SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS). Blood, 2020, 136, 25-26.	1.4	0